Related Experiment Video
Updated: Aug 13, 2026

Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
[The clinical and pathological characteristics and prognosis of pseudomyxoma peritonei]
Zhi-qiang Song1, Wen-ze Wang, Xing-hua Lu
1Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. szqinpumch@yahoo.com.cn
Objective:
To investigate the clinical and pathological characteristics, treatment measures and prognosis of pseudomyxoma peritonei (PMP).
Methods:
The clinical records and follow-up data of the patients with PMP were retrospectively analyzed. Survival analysis (Kaplan-Meier method and Cox regression) was used to investigate the prognosis.
Results:
Thirty-three patients (twenty-two women, eleven men) have a median interval between onset and definite diagnosis of 12 months with an average age of 50. The main clinical presentation includes bloating, abdominal mass and abdominal distention. A delay in diagnosis is common and many patients are labeled as other diseases (84.8%). Positive results were often found in the assistant examinations such as erythrocyte sedimentation rate, gastrointestinal tumor markers (carcinoembryonic antigen, carcinomatous antigen 19-9 and so on), imaging (B ultrasound and computer tomography) and abdominal paracentesis which was usually unsuccessful. The most frequently practiced approach is debulking surgery with the main assistant means of chemotherapy which was lack of the uniform rationale. Benign type of pathological samples accounts for 66.7% of all, while mid-type 21.2% and malignant 12.1%. The general median survival time is 70 months with a follow-up rate of 79%. The pathological type and chemotherapy are main factors which influence the cumulative survival rate (P < 0.05). Up to the end of 2004, sixteen patients died of various complications, multiple organ failure and severe infection, while ten patients survival and seven patients lost.
Conclusions:
PMP is a rare condition of borderline malignancy with its unique clinical and pathological characteristics. Gastrointestinal tumor markers, imaging and abdominal paracentesis are very important to the diagnosis. The existing treatment measures need to be improved further. The pathological type and chemotherapy are main factors which influence the prognosis.
Insights
Pseudomyxoma peritonei (PMP) is a rare borderline malignancy. Diagnosis is often delayed, but pathological type and chemotherapy significantly impact prognosis, necessitating improved treatment strategies.
Area of Science:
- Gastroenterology and Oncology
- Pathology
- Surgical Oncology
Context:
- Pseudomyxoma peritonei (PMP) is a rare neoplastic condition characterized by mucinous ascites.
- Delayed diagnosis is common, with many patients initially misdiagnosed.
- The study retrospectively analyzed clinical and pathological data from 33 PMP patients.
Purpose:
- To investigate the clinical and pathological characteristics of PMP.
- To evaluate treatment modalities and patient prognosis.
- To identify factors influencing survival in PMP patients.
Summary:
- PMP presents with symptoms like bloating and abdominal distention, often with delayed diagnosis.
- Diagnostic tools include tumor markers, imaging, and paracentesis, though the latter is often unsuccessful.
- Debulking surgery combined with chemotherapy is the primary treatment, but lacks standardized protocols. Pathological type and chemotherapy influence survival.
Impact:
- Highlights the diagnostic challenges and unique characteristics of PMP.
- Underscores the need for improved treatment strategies for this rare condition.
- Identifies pathological type and chemotherapy as key prognostic factors, guiding future research and clinical management.
More Related Videos
07:20Intraoperative Detection of Subtle Endometriosis: A Novel Paradigm for Detection and Treatment of Pelvic Pain Associated with the Loss of Peritoneal Integrity
Published on: December 21, 2012
07:54Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019